Opinion|Videos|November 18, 2024
Prospects in First-Line and Maintenance Settings
Author(s)Joshua K. Sabari, MD
Joshua K. Sabari, MD, evaluates the potential of ifinatamab deruxtecan in combination with atezolizumab, with or without platinum-based chemotherapy, as first-line induction or maintenance therapy in ES-SCLC, emphasizing that statistically significant end points such as improved PFS and OS would be essential for clinical application in this patient population.
Episodes in this series
Video content above is prompted by the following:
Given the currently available data on ifinatamab deruxtecan, please evaluate its potential in combination with atezolizumab with or without platinum-based chemotherapy as first-line induction or maintenance therapy in ES-SCLC.
- What would you consider to be statistically significant end points with dual or triple therapy to warrant clinical application in this patient population?
